Zynerba Pharmaceuticals Stock News

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) reported Tuesday f inancial results for the fourth quarter and full year ended December 31, 2021. “In 2022, we look to build on last year’s progress as we continue to enroll patients in our confirmatory pivotal Phase 3 trial in Fragile X syndrome, initiate a Phase 3 program in autism spectrum disorder and report topline results in our Phase 2 trial in 22q11.2 deletion syndrome,” Armando Anido , chairman and chief executive officer of Zynerba stated. “We are committed to achieving our goal of bringing the first pharmaceutical product indicated for the treatment of behavioral symptoms of Fragile X syndrome to market, as well as advancing Zygel in other rare and near rare neuropsychiatric indications.” Q4 And Full Year 2021 Financial Highlights Research and development expenses were $21.4 million for full year 2021, including stock-based compensation of $2.8 million.

Zynerba Pharmaceuticals press release (ZYNE): Q4 GAAP EPS of -$0.22 beats by $0.04.As of December 31, 2021, cash and cash equivalents were $67.8M, compared to $59.2M as of December…

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) –

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc's results for the fourth quarter and full year reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN00

Zynerba Pharmaceuticals (ZYNE) said the European Commission granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel Zygel, for the treatment of…

Provides 10-year market exclusivity in EU upon regulatory approval Devon, PA, February 28, 2022 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, […]

Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval

Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE ), completed enrollment for the 14-week Phase 2 INSPIRE trial of Zygel (Transdermal CBD Gel) in the treatment of behavioral symptoms of 22q11.2 deletion syndrome in children and adolescents. The company expects top-line data from this trial mid-year 2022. “The completion of enrollment in our INSPIRE trial is an important step forward in advancing Zygel as a potential new treatment option for patients suffering from 22q,” stated Armando Anido , chairman and CEO of Zynerba. “Pending results from the INSPIRE trial and subsequent discussion with the FDA on the regulatory path forward, we plan to advance … Full story available on Benzinga.com

Topline data from Phase 2 INSPIRE trial expected mid-year 2022 Topline data from Phase 2 INSPIRE trial expected mid-year 2022

Cresco Labs Taps Megan Kulick To Serve As VP Of Investor Relations Cresco Labs (OTC: CRLBF ) appointed Megan Kulick to the role of senior vice president of investor relations. Kulick has over 20 years of experience in investor relations, equity research, and portfolio management at bulge bracket US banks and cannabis multi-state operators. Most recently, she led investor relations for AYR Wellness Inc (OTCQX: AYRWF ) . Prior to that, Kulick held several senior positions, including the role of senior vice president at PIMCO, director at Merrill Lynch and VP at JPMorgan Chase. "Megan''s experience in the cannabis industry paired with a long and successful career at some of the most prestigious banks and investment managers makes her the perfect fit as the industry evolves and begins to attract more institutional capital," Dennis Olis, Cresco Labs'' CFO said. Botanacor Laboratories & Agricor Laboratories Welcome Richard Strong As Digital Officer & SVP Of Information Technology Agricor Laboratories and Botanacor Laboratories jointly announced that Richard Strong has joined Agricor and Botanacor as digital officer and senior vice president of information technology.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022. "We are excited to have Al join our senior leadership team,” Armando Anido, chairman and CEO of Zynerba , said. “He … Full story available on Benzinga.com

DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rar

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced the appointment of Albert P Parker as the company's new chief legal officer and corporate secretary.  Parker, an accomplished industry executiv

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal o